Alan J Bitonti, 73300 Adams St, Annapolis, MD 21403

6413974, Jul 2, 2002

Feb 9, 1999

09/247052

Jennifer A. Dumont - Flemington NJ
Alan J. Bitonti - Ringoes NJ
David R. Borcherding - Bangor PA
Norton P. Peet - Neshanic Station NJ
Patrick W. Shum - Flemington NJ

Aventis Pharmaceuticals Inc. - Bridgewater NJ

C07D47316

514261, 514266, 544277

The present invention provides novel compounds of the formula (I) wherein R is selected from the group consisting of R2, R2NHâ, or H NâR3â wherein R2 is selected from the group consisting of C -C alkyl and âwherein Z is selected from the group consisting of phenyl, heterocycle and cycloalkyl, each R4 is independently hydrogen or C -C alkyl, and n is an integer 1-8; wherein each C -C alkyl and Z is optionally substituted with 1 to 3 substituents, which may be the same or different, selected from the group consisting of Ha1, OH, and C -C alkyl; R3 is C -C alkylene; and R1 is selected from the group consisting of cyclopentyl and isopropyl, and the pharmaceutically acceptable salts, optical isomers, and hydrates thereof. In addition, the present invention provides a method of inhibiting cell cycle progression. More specifically, the present invention provides a method of inhibiting cyclin dependent kinases, particularly cdk-2.

6479487, Nov 12, 2002

Feb 9, 1999

09/247053

Jennifer A. Dumont - Flemington NJ
Alan J. Bitonti - Acton MA
David R. Borcherding - Bangor PA
Norton P. Peet - Neshanic Station NJ
Patrick W. Shum - Flemington NJ

Aventis Pharmaceuticals Inc. - Bridgewater NJ

C07D47316

5142342, 514261, 514266, 544118, 544277

The present invention provides novel compounds of the formula (I) wherein R is selected from the group consisting of R2, R2NHâ, or R3R4NâR5- wherein R2 is selected from the group consisting of C -C alkyl, Z is selected from the group consisting of phenyl, heterocycle, cycloalkyl, and naphthanlene; and M is selected from the group consisting of hydrogen, C -C alkyl, and wherein each C -C alkyl or Z is optionally substituted with 1 to 3 substituents, which may be the same or different, and which are selected from the group consisting of D, E, wherein each D is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy, and C -C alkoxy; each E is independently selected from the group consisting of Hal, OH, and C -C alkyl; R3 and R4 are selected from the group consisting of hydrogen, C -C alkyl and (CH ) -phenyl, wherein y is an integer 0-8, with the proviso that R3 and R4 not both be hydrogen; R5 is C -C alkylene; and R1 is selected from the group consisting of cyclopentyl, cyclopentenyl and isopropyl, and the pharmaceutically acceptable salts, optical isomers, and hydrates thereof, with the proviso that when R2 is the group wherein n is 1 or greater; R1 is isopropyl or cyclopentyl; R6 is hydrogen, C -C alkyl, or (CH ) -phenyl; and Z is phenyl, heterocycle, or cycloalkyl, that Z is substituted with 1 to 3 substituents, which may be the same or different, and which are selected from the group consisting of In addition, the present invention provides a method of inhibiting cyclin dependent kinases, particularly cdk-2. The present invention also provides a method of preventing apoptosis in neuronal cells and a method of inhibiting the development of neoplasms.

6642231, Nov 4, 2003

Jun 24, 2002

10/178494

Jennifer A. Dumont - Groton MA
Alan J. Bitonti - Acton MA
David R. Borcherding - Bangor PA
Norton P. Peet - North Andover MA
Patrick W. Shum - Flemington NJ

Aventis Pharmaceuticals Inc. - Bridgewater NJ

C07D47316

5142342, 5142634, 51426321, 51426322, 51426333, 5142632, 544118, 544277

The present invention comprises 6-9-Disubstituted 2-[trans-(4-aminocyclohexyl]aminopurines that are useful in inhibiting cyclin dependent kinases, particularly cdk-2. The present invention also provides a method of preventing apoptosis in neuronal cells and a method of inhibiting the development of neoplasms.

7348004, Mar 25, 2008

Jan 5, 2005

11/029003

Robert T. Peters - West Roxbury MA, US
Adam R. Mezo - Waltham MA, US
Daniel S. Rivera - Providence RI, US
Alan J. Bitonti - Acton MA, US
Susan C. Low - Pepperell MA, US
James Stattel - Leominster MA, US

Syntonix Pharmaceuticals, Inc. - Waltham MA

A61K 39/00
C07K 16/00
C07K 1/00
C07K 14/00
C12P 21/08

4241781, 5303871, 5303873, 5303917, 530402

The invention relates to a chimeric monomer-dimer hybrid protein wherein said protein comprises a first and a second polypeptide chain, said first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and said second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.

7404956, Jul 29, 2008

May 6, 2004

10/841250

Robert T. Peters - West Roxbury MA, US
Adam R. Mezo - Waltham MA, US
Daniel S. Rivera - Providence RI, US
Alan J. Bitonti - Acton MA, US
Susan C. Low - Pepperell MA, US

Syntonix Pharmaceuticals, Inc. - Waltham MA

A61K 39/00
C07K 16/00
C07K 1/00
C07K 14/00
C12P 21/08

4241781, 5303871, 5303873, 5303917, 530402

The invention relates to a chimeric monomer-dimer hybrid protein wherein said protein comprises a first and a second polypeptide chain, said first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and said second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.

7566565, Jul 28, 2009

Mar 23, 2007

11/728045

Robert T. Peters - West Roxbury MA, US
Alan J. Bitonti - Acton MA, US

Syntonix Pharmaceuticals, Inc. - Waltham MA

C12N 15/00
C12N 5/00

435325, 435383

Compositions and methods for preparing Factor IX, Factor IX-containing fusion proteins, and Factor IX-containing conjugates with processing of Factor IX propeptide by PC5, are provided. In one embodiment PC5 is used to process a precursor polypeptide for a Factor IX-Fc monomer-dimer hybrid.

7795400, Sep 14, 2010

Jun 22, 2009

12/489391

Robert T. Peters - West Roxbury MA, US
Alan J. Bitonti - Acton MA, US

Syntonix Pharmaceuticals, Inc. - Waltham MA

A61K 38/48
C12Q 1/00
C12N 9/00

530384, 435 4, 435183

Compositions and methods for preparing Factor IX, Factor IX-containing fusion proteins, and Factor IX-containing conjugates with processing of Factor IX propeptide by PC5, are provided. In one embodiment PC5 is used to process a precursor polypeptide for a Factor IX-Fc monomer-dimer hybrid.

7862820, Jan 4, 2011

Oct 27, 2006

11/588431

Robert T. Peters - West Roxbury MA, US
Adam R. Mezo - Waltham MA, US
Daniel S. Rivera - Providence RI, US
Alan J. Bitonti - Acton MA, US
Susan C. Low - Pepperell MA, US

Syntonix Pharmaceuticals, Inc. - Waltham MA

A61K 39/00
C07K 16/00
C12P 21/08

4241791, 4241331, 4241341, 4241781, 5303871, 5303873, 5303911, 5303917, 5303919

The invention relates to a chimeric monomer-dimer hybrid protein that comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first polypeptide chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.